EUR 27.0
(-0.37%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 198.7 Million EUR | -14.41% |
2022 | 232.14 Million EUR | -2.84% |
2021 | 238.92 Million EUR | -12.37% |
2020 | 272.65 Million EUR | 5.34% |
2019 | 258.82 Million EUR | -7.9% |
2018 | 281.03 Million EUR | -0.66% |
2017 | 282.91 Million EUR | -0.88% |
2016 | 285.43 Million EUR | 2.16% |
2015 | 279.4 Million EUR | -3.54% |
2014 | 289.67 Million EUR | 5.06% |
2013 | 275.72 Million EUR | 22.48% |
2012 | 225.12 Million EUR | 2.82% |
2011 | 218.95 Million EUR | 2.08% |
2010 | 214.49 Million EUR | 2.8% |
2009 | 208.65 Million EUR | 8.76% |
2008 | 191.85 Million EUR | 7.51% |
2007 | 178.44 Million EUR | -1.94% |
2006 | 181.97 Million EUR | -7.8% |
2005 | 197.37 Million EUR | 55.5% |
2004 | 126.92 Million EUR | 28.94% |
2003 | 98.44 Million EUR | 2.27% |
2002 | 96.26 Million EUR | 11.04% |
2001 | 86.69 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 184.68 Million EUR | 0.0% |
2023 Q2 | 202.74 Million EUR | 0.0% |
2023 Q4 | 198.7 Million EUR | 0.0% |
2023 FY | 198.7 Million EUR | -14.41% |
2022 FY | 232.14 Million EUR | -2.84% |
2022 Q4 | 232.14 Million EUR | 0.0% |
2022 Q2 | 237.9 Million EUR | 0.0% |
2021 Q4 | 238.92 Million EUR | 0.0% |
2021 Q2 | 244.75 Million EUR | 0.0% |
2021 FY | 238.92 Million EUR | -12.37% |
2020 FY | 272.65 Million EUR | 5.34% |
2020 Q2 | 275.72 Million EUR | 0.0% |
2020 Q4 | 272.65 Million EUR | 0.0% |
2019 Q2 | 271.05 Million EUR | 0.0% |
2019 Q4 | 258.82 Million EUR | 0.0% |
2019 FY | 258.82 Million EUR | -7.9% |
2018 Q2 | 257.8 Million EUR | 0.0% |
2018 Q4 | 281.03 Million EUR | 0.0% |
2018 FY | 281.03 Million EUR | -0.66% |
2017 Q4 | 282.91 Million EUR | 0.0% |
2017 FY | 282.91 Million EUR | -0.88% |
2017 Q2 | 263.61 Million EUR | 0.0% |
2016 FY | 285.43 Million EUR | 2.16% |
2016 Q4 | 285.43 Million EUR | 0.0% |
2016 Q2 | 260.3 Million EUR | 0.0% |
2015 Q4 | 279.4 Million EUR | 0.0% |
2015 Q2 | 263.61 Million EUR | 0.0% |
2015 FY | 279.4 Million EUR | -3.54% |
2014 Q4 | 289.67 Million EUR | 0.0% |
2014 FY | 289.67 Million EUR | 5.06% |
2014 Q2 | 250.48 Million EUR | 0.0% |
2013 Q2 | 259.38 Million EUR | 0.0% |
2013 Q4 | 275.72 Million EUR | 0.0% |
2013 FY | 275.72 Million EUR | 22.48% |
2012 Q2 | 193.81 Million EUR | 0.0% |
2012 Q1 | 193.81 Million EUR | -11.48% |
2012 Q4 | 225.12 Million EUR | -15.84% |
2012 FY | 225.12 Million EUR | 2.82% |
2012 Q3 | 267.49 Million EUR | 38.01% |
2011 Q2 | 207.63 Million EUR | 0.0% |
2011 FY | 218.95 Million EUR | 2.08% |
2011 Q4 | 218.95 Million EUR | 0.0% |
2010 Q4 | 214.49 Million EUR | 0.0% |
2010 FY | 214.49 Million EUR | 2.8% |
2010 Q2 | 185.51 Million EUR | 0.0% |
2009 Q4 | 208.65 Million EUR | 0.0% |
2009 FY | 208.65 Million EUR | 8.76% |
2008 FY | 191.85 Million EUR | 7.51% |
2007 FY | 178.44 Million EUR | -1.94% |
2006 FY | 181.97 Million EUR | -7.8% |
2005 FY | 197.37 Million EUR | 55.5% |
2004 FY | 126.92 Million EUR | 28.94% |
2003 FY | 98.44 Million EUR | 2.27% |
2002 FY | 96.26 Million EUR | 11.04% |
2001 FY | 86.69 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Laboratorios Farmaceuticos Rovi, S.A. | 256.39 Million EUR | 22.5% |
Vetoquinol SA | 165.12 Million EUR | -20.336% |
Valneva SE | 341.14 Million EUR | 41.755% |
AB Science S.A. | 46.5 Million EUR | -327.24% |
Nanobiotix S.A. | 95.74 Million EUR | -107.542% |
PHAXIAM Therapeutics S.A. | 25.69 Million EUR | -673.306% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | -4269.936% |
BioSenic S.A. | 32.26 Million EUR | -515.86% |
ABIVAX Société Anonyme | 131.05 Million EUR | -51.62% |
Formycon AG | 387.61 Million EUR | 48.737% |